Houston Methodist (In-person and virtual attendance options available)

OVERVIEW

Presented by the Houston Methodist Dr. Mary and Ron Neal Cancer Center

This annual symposium, dedicated to the science and clinical care of solid and hematologic malignancies, brings together Houston Methodist scientists and physicians from a broad spectrum of fields, including basic, clinical, and epidemiological research. A wide range of topics will be covered, from innovative translational science to clinical updates with strategies for implementation in current clinical practice. The program will provide education focused on improving patient care, research collaboration and leading medicine.

TARGET AUDIENCE

Physician scientists, practicing oncologists, physician assistants, advanced nurse practitioners, oncology nurses, residents, fellows, medical students, allied health care professionals and clinical research associates will benefit from this course.

LEARNING OBJECTIVES

At the conclusion of this activity, the participant should be able to: 

• Discuss the fundamental mechanisms of cellular immunotherapy in hematologic malignancies
• Describe the approved cell therapy options in hematologic malignancies including CAR-T cell
• Identify new cellular therapies in the pipeline for these diseases

ACCREDITATION

• 6.75 AMA PRA Category 1 Credit™

  Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

  Houston Methodist designates this Live activity for a maximum of 6.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• 6.75 Attendance

For more information please visit the official event page.